Congenital Hematological Disorder (DBCOND0081791)

Identifiers

Synonyms
Congenital haematological disorder / Congenital bleeding disorders / Congenital Bleeding Disorder / Congenital hematological disorder

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT03016806
Umbilical Cord Blood Transplantation From Unrelated Donorstreatment1recruiting
NCT01230021
Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiencytreatment3completed
NCT01779921
Treatment of Congenital Factor VII DeficiencyNot AvailableNot Availablecompleted
NCT06574984
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A PatientsNot AvailableNot Availablenot_yet_recruiting
NCT00571584
High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitorstreatment4completed
NCT03196284
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitorstreatment2completed
NCT02035384
Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia ANot AvailableNot Availablecompleted
NCT01562587
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding Statetreatment1completed
NCT00956345
Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia Btreatment1completed
NCT00703911
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With InhibitorsNot AvailableNot Availablecompleted
NCT01563471
Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteerstreatment1completed
NCT01493778
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia Atreatment3completed
NCT00882778
PROPACT: Retrospective Prophylaxis Patient Case CollectionNot AvailableNot Availablecompleted
NCT00837356
Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjectstreatment1completed
NCT01988532
Impact of Pain on Functional Impairment and Quality of Life in Adults With HemophiliaNo drug interventionsNot AvailableNot Availablecompleted
NCT01272206
Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male SubjectsNo drug interventionstreatment1completed
NCT01082406
Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjectstreatment1completed
NCT01555749
Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese SubjectsNo drug interventionstreatment1completed
NCT02207218
To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in JapanNot AvailableNot Availablecompleted
NCT00710619
Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IXNot AvailableNot Availablecompleted
NCT01561924
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastographydiagnostic1completed
NCT00108758
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophiliatreatment2completed
NCT00713648
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiencyprevention3completed
NCT00984126
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015treatment3completed
NCT02141074
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia Btreatment3completed
NCT00697320
Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in GermanyNot AvailableNot Availablecompleted
NCT00951873
A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteerstreatment1completed
NCT01561391
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgerytreatment4completed
NCT00056589
Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiencytreatment1completed
NCT00922792
Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and Btreatment1completed
NCT01949792
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitorstreatment1completed
NCT01238367
A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543treatment1completed
NCT01503567
Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing CountriesNo drug interventionsNot AvailableNot Availablecompleted
NCT01138501
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia Atreatment3completed
NCT01579968
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing SurgeryNot AvailableNot Availablecompleted
NCT01228669
Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or BNo drug interventionstreatment1completed
NCT01830712
A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With InhibitorsNot AvailableNot Availablecompleted
NCT01395810
Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773treatment3completed
NCT01579955
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical PracticeNot AvailableNot Availablecompleted
NCT02137850
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia Atreatment3completed
NCT01476423
Observational Registry of the Treatment of Glanzmann's ThrombastheniaNot AvailableNot Availablecompleted
NCT01848002
Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteerstreatment1completed
NCT02568202
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)No drug interventionsNot AvailableNot Availablecompleted
NCT02490787
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjectstreatment1completed
NCT02941354
Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia Atreatment1completed
NCT03528551
A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia Atreatment3completed
NCT01392547
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitorstreatment3completed
NCT01234545
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and InhibitorsNot AvailableNot Availablecompleted
NCT01876745
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in JapanNot AvailableNot Availablecompleted
NCT02920398
A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia Atreatment1completed
NCT00951405
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitorsprevention2completed
NCT00108797
Trial of NovoSeven® in Haemophilia - Joint Bleedstreatment4completed
NCT01386528
Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia Btreatment3completed
NCT01489111
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.treatment3completed
NCT01253811
Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiencytreatment3completed
NCT01333111
Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patientstreatment3completed
NCT00486278
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleedstreatment2completed
NCT02994407
Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia Atreatment1completed
NCT02938585
Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia Atreatment3completed
NCT00822185
Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteerstreatment1completed
NCT01731600
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia Atreatment3completed
NCT03075670
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia Btreatment1completed
NCT03449342
Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Periodtreatment4completed
NCT02541942
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 TrialNo drug interventionsother2completed
NCT01631942
A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia SubjectsNo drug interventionstreatment1terminated
NCT01586936
Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With InhibitorsNot AvailableNot Availablecompleted
NCT01312636
Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII DeficiencyNot AvailableNot Availablecompleted
NCT02670213
A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in JapanNot AvailableNot Availableenrolling_by_invitation
NCT01220141
Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or BNot AvailableNot Availablecompleted
NCT01561417
Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjectstreatment1completed
NCT01205724
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia Atreatment1completed
NCT00853086
Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia DatabaseNot AvailableNot Availablecompleted
NCT00840086
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjectstreatment3completed
NCT01692925
Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia Atreatment1completed
NCT03179748
Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A PatientsNot AvailableNot Availablecompleted
NCT01562457
Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding Statetreatment1completed
NCT01365520
A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia Atreatment1completed
NCT01322620
Survey Evaluating the Psychosocial Effects of Living With HaemophiliaNo drug interventionsNot AvailableNot Availablecompleted
NCT01467427
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.treatment3completed
NCT02241694
To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily LivesNo drug interventionsNot AvailableNot Availablecompleted
NCT01288391
Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B PatientsNo drug interventionstreatment1completed
NCT00978380
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725prevention3completed
NCT01480180
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia Atreatment3completed
NCT01847989
Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteerstreatment1completed
NCT01862367
Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational StudyNot AvailableNot Availablecompleted
NCT02084810
Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjectstreatment1withdrawn
NCT00104455
Dose Response to Recombinant Factor VIIa When Administered for Bleedtreatment1completed
NCT01959555
Project to Update the Study of Congenital Haemophilia in SpainNo drug interventionsNot AvailableNot Availablecompleted